Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2021 | Abemaciclib in patients with p16ink4a negative, relapsed mesothelioma

Malignant mesotheliomas frequently harbor loss of CDK2NA which is associated with shorter survival and may represent a novel treatment strategy for these patients. Dean A. Fennell, PhD, FRCP, University Hospitals of Leicester NHS Trust, Leicester, UK, presents findings of a Phase II study investigating the efficacy of abemaciclib, a CDK4/6 inhibitor in patients with p16ink4a negative relapsed mesothelioma in the MiST2 study (NCT03654833). This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.